US 12,473,442 B2
Preparation and applications of biocompatible conductive 3D hydrogels based on cellulose nanofibrils for diagnostics and intervention of neurodegenerative and cardiac diseases
Paul Gatenholm, Riner, VA (US); and Erdem Karabulut, Oslo (NO)
Assigned to Ocean Tunicell AS, Blomsterdalen (NO)
Filed by Ocean Tunicell AS, Blomsterdalen (NO)
Filed on Sep. 14, 2020, as Appl. No. 17/020,345.
Application 17/020,345 is a continuation of application No. 15/963,076, filed on Apr. 25, 2018, granted, now 10,774,227.
Claims priority of provisional application 62/489,653, filed on Apr. 25, 2017.
Prior Publication US 2020/0407577 A1, Dec. 31, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C09D 11/14 (2006.01); A61L 27/08 (2006.01); A61L 27/20 (2006.01); A61L 27/36 (2006.01); A61L 27/38 (2006.01); A61L 27/44 (2006.01); A61L 27/50 (2006.01); A61N 1/05 (2006.01); A61N 1/36 (2006.01); A61N 1/362 (2006.01); B33Y 70/00 (2020.01); B33Y 80/00 (2015.01); B82Y 30/00 (2011.01); C09D 4/00 (2006.01); C09D 7/40 (2018.01); C09D 11/03 (2014.01); C09D 11/037 (2014.01); C09D 11/30 (2014.01); C09D 11/324 (2014.01); C09D 11/38 (2014.01); C09D 11/52 (2014.01); C12N 5/00 (2006.01); C12N 5/071 (2010.01); C12N 5/077 (2010.01); C12N 5/0793 (2010.01); C12N 5/09 (2010.01)
CPC C09D 11/14 (2013.01) [A61L 27/08 (2013.01); A61L 27/20 (2013.01); A61L 27/36 (2013.01); A61L 27/3625 (2013.01); A61L 27/367 (2013.01); A61L 27/3675 (2013.01); A61L 27/3691 (2013.01); A61L 27/38 (2013.01); A61L 27/3826 (2013.01); A61L 27/383 (2013.01); A61L 27/3834 (2013.01); A61L 27/3873 (2013.01); A61L 27/3895 (2013.01); A61L 27/443 (2013.01); A61L 27/50 (2013.01); A61N 1/0536 (2013.01); A61N 1/3605 (2013.01); A61N 1/36067 (2013.01); A61N 1/36082 (2013.01); A61N 1/362 (2013.01); B33Y 70/00 (2014.12); B33Y 80/00 (2014.12); C09D 4/00 (2013.01); C09D 7/67 (2018.01); C09D 11/03 (2013.01); C09D 11/037 (2013.01); C09D 11/30 (2013.01); C09D 11/324 (2013.01); C09D 11/38 (2013.01); C09D 11/52 (2013.01); C12N 5/0062 (2013.01); C12N 5/0619 (2013.01); C12N 5/0657 (2013.01); C12N 5/0691 (2013.01); C12N 5/0693 (2013.01); C12N 5/0697 (2013.01); A61L 2300/412 (2013.01); A61L 2300/64 (2013.01); A61L 2400/12 (2013.01); A61L 2430/20 (2013.01); A61L 2430/32 (2013.01); B82Y 30/00 (2013.01); C12N 2501/90 (2013.01); C12N 2501/999 (2013.01); C12N 2513/00 (2013.01); C12N 2533/78 (2013.01); C12N 2539/00 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A biocompatible and electrically conductive three-dimensional (3D) hydrogel comprising nanocellulose, wherein the 3D hydrogel in its final form for bioprinting or injecting into tissue is non-dried, wherein the nanocellulose comprises one or more of bacterial cellulose, cellulose nanofibrils, cellulose nanocrystals, or disintegrated bacterial cellulose, wherein the nanocellulose is isolated from tunicates, bacteria, plants, and/or algae, wherein the non-dried 3D hydrogel further comprises graphitic-based electrically conductive nanomaterials, and wherein the non-dried 3D hydrogel in its final form is bioprinted to form three-dimensionally bioprinted structures or injected into tissue.